Mylan Settles Patent Suit with Novo Nordisk over Generic Ozempic
October 7, 2024 10:46
Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement in the US over a patent infringement lawsuit regarding generic Ozempic, a drug used for blood sugar and weight loss.